Fluvoxamine
 |
|
| Clinical data | |
|---|---|
| Trade names | Faverin, Fevarin, Floxyfral, Dumyrox, Luvox |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682275 |
| Pregnancy category |
|
| Routes of administration |
Oral (tablets) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 53% (90% confidence interval: 44–62%) |
| Protein binding | 80% |
| Metabolism | Hepatic (via enzymes. Mostly via oxidative demethylation) |
| Biological half-life | 12–13 hours (single dose), 22 hours (repeated dosing) |
| Excretion | Renal (98%; 94% as metabolites, 4% as unchanged drug) |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.125.476 |
| Chemical and physical data | |
| Formula | C15H21F3N2O2 |
| Molar mass | 318.335 |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?)
|
|
Fluvoxamine (brand names: Faverin, Fevarin, Floxyfral, Dumyrox and Luvox) is a medication which functions as a selective serotonin reuptake inhibitor (SSRI) and σ1 receptor agonist. Fluvoxamine is used primarily for the treatment of obsessive–compulsive disorder (OCD), and is also used to treat major depressive disorder and anxiety disorders such as panic disorder and post-traumatic stress disorder. Fluvoxamine CR (controlled release) is approved to treat social anxiety disorder.
The FDA has added a black box warning for this drug in reference to increased risks of suicidal thoughts and behavior in young adults and children.
Fluvoxamine's only FDA approved indication is in the treatment of OCD, although in other countries (e.g. Australia,UK and Russian Federation) it also has indications for major depressive disorder. Fluvoxamine has been found to be useful in the treatment of major depressive disorder, anxiety disorders such as panic disorder, social anxiety disorder, and posttraumatic stress disorder, and other obsessive–compulsive spectrum disorders. Fluvoxamine is indicated for children and adolescents with OCD. The drug works long-term, and retains its therapeutic efficacy for at least a year. It has also been found to possess some analgesic properties in line with other SSRIs and tricyclic antidepressants.
Some evidence shows fluvoxamine may be a helpful adjunct in the treatment of schizophrenia, improving the depressive, negative, and cognitive symptoms of the disorder. Its actions at the sigma receptor may afford it a unique advantage among antidepressants in treating the cognitive symptoms of schizophrenia.
...
Wikipedia